MPHOSPH8: A Drug Target and Biomarker (G54737)

Target Name: MPHOSPH8

NCBI ID: G54737

MPHOSPH8

Other Name(s): M-phase phosphoprotein, mpp | HSMPP8 | Twa3 | Mpp8 | TWA3 | MPP8_HUMAN | RP11-523H24.1 | M-phase phosphoprotein 8 | M-phase phosphoprotein, mpp8 | MPP8 | Two hybrid-associated protein 3 with RanBPM | mpp8 | two hybrid-associated protein 3 with RanBPM

MPHOSPH8: A Drug Target and Biomarker

MPHOSPH8 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is melanophilin-converting enzyme 8, and it is a member of the superfamily of cation channels. MPHOSPH8 is involved in the regulation of melanin synthesis and helps to maintain the dark brown color of the skin.

MPHOSPH8 has also been shown to play a role in the development and progression of certain diseases, including cancer. For example, studies have shown that high levels of MPHOSPH8 are associated with poor prognosis in patients with pancreatic cancer. Additionally, MPHOSPH8 has been shown to be involved in the regulation of blood pressure, and high levels of MPHOSPH8 have been associated with an increased risk of hypertension.

Despite these promising findings, more research is needed to fully understand the role of MPHOSPH8 in disease. One way to do this is to investigate its potential as a drug target. By targeting MPHOSPH8 with small molecules or antibodies, researchers may be able to disrupt its function and study its effects on various diseases.

In addition to its potential as a drug target, MPHOSPH8 has also been shown to be a valuable biomarker for certain diseases. For example, MPHOSPH8 has been used as a biomarker for pancreatic cancer, as high levels of MPHOSPH8 are associated with poor prognosis in these patients. Additionally, MPHOSPH8 has been shown to be involved in the regulation of blood pressure, and studies have shown that individuals with hypertension may have lower levels of MPHOSPH8 than those without hypertension.

These findings suggest that MPHOSPH8 may be a valuable biomarker for hypertension, and that it may also be a potential drug target for certain diseases. Further research is needed to fully understand its role and to develop effective treatments based on its properties.

Protein Name: M-phase Phosphoprotein 8

Functions: Heterochromatin component that specifically recognizes and binds methylated 'Lys-9' of histone H3 (H3K9me) and promotes recruitment of proteins that mediate epigenetic repression (PubMed:20871592, PubMed:26022416). Mediates recruitment of the HUSH complex to H3K9me3 sites: the HUSH complex is recruited to genomic loci rich in H3K9me3 and is required to maintain transcriptional silencing by promoting recruitment of SETDB1, a histone methyltransferase that mediates further deposition of H3K9me3, as well as MORC2 (PubMed:26022416, PubMed:28581500). Binds H3K9me and promotes DNA methylation by recruiting DNMT3A to target CpG sites; these can be situated within the coding region of the gene (PubMed:20871592). Mediates down-regulation of CDH1 expression (PubMed:20871592). Also represses L1 retrotransposons in collaboration with MORC2 and, probably, SETDB1, the silencing is dependent of repressive epigenetic modifications, such as H3K9me3 mark. Silencing events often occur within introns of transcriptionally active genes, and lead to the down-regulation of host gene expression (PubMed:29211708). The HUSH complex is also involved in the silencing of unintegrated retroviral DNA by being recruited by ZNF638: some part of the retroviral DNA formed immediately after infection remains unintegrated in the host genome and is transcriptionally repressed (PubMed:30487602)

The "MPHOSPH8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPHOSPH8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets